Radiation with concomitant superselective intra-arterial cisplatin infusion for maxillary sinus squamous cell carcinoma
- 88 Downloads
To assess the efficacy and prognostic factors after superselective intra-arterial chemoradiation (RADPLAT) for maxillary sinus squamous cell carcinoma (MS-SCC).
Materials and methods
Prognostic significance of age, gender, T and N factors, gross tumor volume of the primary-site (GTV), total cisplatin dosage, and total cisplatin dosage per GTV (CDDP/GTV) for primary-site recurrence-free survival rate (PRFS) were analyzed. RADPLAT was administered to 27 patients. The median follow-up period was 42.1 months.
The 3-year rates of overall survival and PRFS were 59.2% and 53.9%, respectively. In univariate analysis, age, male, and total cisplatin dosage were significant factors for PRFS. In multivariate analysis, lymph node metastasis was significant factors for PRFS, and gender and total cisplatin dosage weakly influenced PRFS. In acute phase, no patient showed ≥ grade 3 hematologic toxicity, and grade 3 mucositis developed in 5 patients. Late toxicities were recognized in 3 patients (grade 2 phlegmon of the face, grade 3 maxillofacial osteonecrosis, and retinopathy). Twelve patients (44%) experienced recurrences. Of them, 8 patients showed recurrence at the primarysite.
RADPLAT was effective for MS-SCC, with acceptable toxicity. Total cisplatin dosage is suggested to be important for primary tumor control.
KeywordsRADPLAT Maxillary sinus squamous cell carcinoma Radiotherapy Cisplatin per tumor volume Prognostic factor
This research was supported by Grand-in-Aid (B-10, 2017) of Gunma Prefectural Cancer Center in Japan.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in the present study were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.Committee JSfhaNCCR. Report of Head and Neck Cancer Registry of Japan Clinical Statistics of Registered Patients, 2015.Google Scholar
- 2.Ogawa K, Toita T, Kakinohana Y, et al. Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications. Oncol Rep. 2001;8:315–9.Google Scholar
- 9.Robbins KT, Kumar P, Harris J, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol. 2005;23:1447–544.CrossRefGoogle Scholar
- 10.Ethics guideline for medical research concerning humans. Ministry of education, culture, sports, science and technology, Japan. December 22, 2014.Google Scholar
- 11.Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003.Google Scholar
- 13.Homma A, Onimaru R, Matsuura K, et al. Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (Japan Clinical Oncology Group 1212): Dose-finding phase. Head Neck. 2018;40:475–84.CrossRefGoogle Scholar
- 17.Al-Mamgani A, Monserez D, Rooij P, Verduijn GM, Hardillo JA, Levendag PC. Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo)radiation. Oral Oncol. 2012;48:905–11.CrossRefGoogle Scholar